Indegene Limited announced the appointment of Ms. Jill Mary De Simone as an Independent Director. This approval was granted by shareholders at the 28th Annual General Meeting (AGM) held on August 13, 2026. Ms. De Simone brings extensive experience in the biopharmaceutical industry and governance across global healthcare organizations, which is expected to enhance the company’s strategic direction.
Board Strengthened with New Independent Director
Indegene Limited has officially welcomed Ms. Jill Mary De Simone as an Independent Director to its Board of Directors. The appointment was formally approved by the company’s shareholders during the 28th Annual General Meeting (AGM), which took place virtually on Thursday, August 13, 2026. This move is set to bolster the company’s governance and strategic oversight.
Experienced Leadership Joins Indegene
Ms. De Simone’s appointment comes with a wealth of experience in the biopharmaceutical sector. She is recognized as an accomplished executive and board director with a proven track record in driving growth, innovation, and governance within global healthcare organizations. Her career includes significant leadership roles at major pharmaceutical companies such as Merck, Teva, and Bristol Myers Squibb, where she managed substantial P&L responsibilities and spearheaded the launch of transformative therapies in areas like oncology and women’s health.
Currently, Ms. De Simone actively advises preclinical and early-stage companies on commercialization strategies and leadership transitions. She also serves on the boards of various public and private life sciences companies and contributes to advisory boards focused on AI in healthcare. Her strategic acumen, leadership style, and commitment to purpose-driven cultures are expected to bring significant value to Indegene.
Terms of Appointment
Ms. Jill Mary De Simone’s tenure as an Independent Director will commence on January 22, 2026, and will extend for a period of three years, concluding on January 21, 2029. The company has confirmed that Ms. De Simone is not debarred from holding such an office by any regulatory authority. This appointment is detailed further in Annexure I, as per regulatory requirements.
Source: BSE
